Gefitinib, erlotinib, and lapatinib are EGF inhibitors clinically approved by the FDA for the treatment of advanced non-small cell lung cancer (NSCLC); icotinib has been registered for such use in Asia [11]. Here, EGF is linked to non-small cell lung carcinoma.